Brainstorm Cell Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview

Brainstorm Cell Therapeutics

01/11/2024 14:05

* Brainstorm Cell Therapeutics Inc  BCLI.OQ   BCLI.O  is
expected
to show no change in quarterly revenue when it reports 
results on November 5 (estimated) for the period ending
September 30 2024
    * 
    * ​LSEG's mean analyst estimate for Brainstorm Cell
Therapeutics
Inc is for a loss of 57 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Brainstorm
Cell
Therapeutics Inc is $22.51​, above​ its last closing price
of $1.87. ​​​

This summary was machine generated November 1 at 14:05 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)